{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T05:30:14Z","timestamp":1738992614503,"version":"3.37.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,9,29]],"date-time":"2008-09-29T00:00:00Z","timestamp":1222646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background:<\/jats:italic>The lack of controlled trials on the treatment of pemphigus and pemphigoid diseases limits an evidence\u2010based therapy of these disorders.The aim of this survey was to assess the current treatment standards at German dermatological hospitals and the need for future therapeutic trials.<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic>A two\u2010page questionnaire was sent to 42 German academic and non\u2010academic dermatological hospitals and evaluated at the Department of Dermatology, University Medical Center, Freiburg.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic>The response rate was 76%. Topical clobetasol propionate treatment was regarded as first line therapy of bullous pemphigoid in 27% of the hospitals. More than 50% used systemic corticosteroids at an initial dose of \u2264 1 mg\/kg prednisolone\u2010equivalent in pemphigus and pemphigoid. Azathioprine is used as first line adjuvant in pemphigoid and pemphigus treatment in 69% and 81% of the hospitals, respectively. Dapsone and mycophenolate mofetil represent alternative options, as well as cyclophosphamide\u2010dexamethasone\u2010pulse therapy in pemphigus. Immunosuppressive treatment of pemphigoid and pemphigus is terminated by 58% and 46% of the hospitals 1\u20133 months after clinical remission, respectively, but the given time points appeared to be variable.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic>The high response rate to this survey demonstrates the interest in this topic. The variability of the answers regarding initial doses of corticosteroids and time points for termination of therapy indicates the need for the establishment of guidelines and for controlled therapeutic trials.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2008.06872.x","type":"journal-article","created":{"date-parts":[[2009,2,20]],"date-time":"2009-02-20T19:19:43Z","timestamp":1235157583000},"page":"227-233","source":"Crossref","is-referenced-by-count":8,"title":["Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid"],"prefix":"10.1111","volume":"7","author":[{"given":"Silke C.","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ocko","family":"Kautz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Bruckner\u2010Tuderman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2006.027"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2007.00033.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0353.2004.04517.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-002-0369-1"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22504.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.903"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592"},{"key":"e_1_2_7_9_2","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","author":"Khumalo N","year":"2005","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.05.024"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04835.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220061016"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781444300161"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.11.1447"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1536"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1399-0012.1996.tb00651.x","article-title":"Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)","volume":"10","author":"Allison AC","year":"1996","journal-title":"Clin Transplant"},{"key":"e_1_2_7_17_2","first-page":"205","article-title":"Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases","volume":"76","author":"Schmidt E","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.1.25"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690060083010"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb07104.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0378.2005.04747.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.5.570"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.8.1051"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06602.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06342.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19529.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04838.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-002-0368-1"},{"key":"e_1_2_7_29_2","first-page":"664","article-title":"Weaning of systemic steroid treatment in pemphigus","volume":"5","author":"Stamm G","year":"1995","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_30_2","first-page":"4","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pfutze M","year":"2007","journal-title":"Eur J Dermatol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2008.06872.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2008.06872.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T20:52:41Z","timestamp":1738961561000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2008.06872.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,20]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1610-0387.2008.06872.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06872.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"type":"print","value":"1610-0379"},{"type":"electronic","value":"1610-0387"}],"subject":[],"published":{"date-parts":[[2009,2,20]]}}}